“Whispers Over My Shoulder”: A Physician’s Perspective About Aspects of Care for a Patient with Cholangiocarcinoma

October 2020, Vol 1, No 2

Cancer is a personal journey. We often see and hear from patients, families, and their caregivers about how this disease changes their lives. However, what is often missing is a physician’s view of the role that the physician plays in the battle against cancer.

At the 2020 virtual conference of the Cholangiocarcinoma Foundation, Mairéad McNamara, MBBCh, PhD, MRCPUK, Senior Lecturer and Honorary Consultant in Medical Oncology, the Christie NHS Foundation Trust, Manchester, England, related her personal odyssey in the treatment of patients with cancer.

When oncologists approach the treatment of a new patient, they rely on the best evidence available, such as the guidelines of the National Comprehensive Cancer Network or other national organizations.

However, as Dr McNamara noted, “What is clear is that there are many shades of gray,” especially when the patient’s clinical picture does not fit neatly into available guidelines, and no good evidence is available for alternate therapies.

Dr McNamara equated the task of trying to develop a treatment plan for such patients to putting together a jigsaw puzzle. The individual pieces, such as the patient’s clinical history, bloodwork results, imaging studies, and biopsy results, need to be combined with the patient’s performance status, comorbidities, and any current medications, as well as the patient’s wishes and expectations.

Empathy and Compassion

In addition to the clinical aspects of providing care for patients with cancer, Dr McNamara emphasized that empathy and compassion in healthcare play vital roles in the patient experience, and these are key components of the physician–patient relationship.

Physicians expressing empathy is a highly effective and powerful tool, Dr McNamara said, which builds patient trust, calms anxiety, and improves health outcomes. She pointed out that persistent exposure to death and professional detachment from the patient experience very often lead many patients, families, and caregivers to see physicians as cold or uncaring. But she added that physicians are not immune to the grief and stress that patients and their caregivers experience. And like their patients, physicians manage their grief and stress in unique ways.

In developing her presentation, Dr McNamara said that her research led her to several published articles on physicians’ personal journeys in confronting grief.

One book in particular that was helpful in understanding how physicians cope with death was by James W. Forsythe, MD, HMD, author of About Death from a Cancer Doctor’s Perspective. The common themes that ran through Dr Forsythe’s book were the same themes that patients struggle with, including anger, fear, denial, and frustration. Furthermore, one of the most often asked questions by physicians is, “How can I cope, if at all?”

What is the reality for physicians when one of their patients dies? An article discussing physicians’ feelings about their patients’ death explored the emotional experiences of physicians who care for dying patients.1 Dr McNamara noted that physicians recall 3 categories of patient death: the “good death,” the “overtreated death,” and, the emotionally most powerful for physicians, the “shocking or unexpected death,” which leaves many questions unanswered for physicians.

Dr McNamara closed her remarks by reminding the attendees that it is important to remember that although physicians often need to give patients and their families bad news, “at the end of the day, people will not remember what you said or did; they will remember how you made them feel.”

Reference

  1. Jackson VA, Sullivan AM, Gadmer NM, et al. “It was haunting...”: physicians’ descriptions of emotionally powerful patient deaths. Acad Med. 2005;80:648-656.

Related Items

Biomarker Discovery and Early Detection in CCA
June 2025, Vol 6, No 2
Experts unveiled a roadmap for translating cutting-edge biomarkers into clinical practice, paving the way for improved early detection and personalized care in high-risk populations with cholangiocarcinoma (CCA).
Translational Science and Discovery in CCA
June 2025, Vol 6, No 2
Leading experts explored groundbreaking advancements in tumor microenvironments, biomarker validation, and innovative therapies, paving the way for transformative precision medicine in cholangiocarcinoma (CCA) care.
Advancements in Cholangiocarcinoma Diagnosis and Treatment: Radiomics, Biomarkers, and Optimal Biliary Decompression
June 2025, Vol 6, No 2
Cutting-edge advancements in tumor microenvironments, therapeutic resistance, biomarker validation, and innovative treatments are paving the way for breakthroughs in precision medicine.
Pathology in CCA
June 2025, Vol 6, No 2
Experts in cholangiocarcinoma (CCA) have explored the transformative role of artificial intelligence in improving CCA diagnosis, predictive marker identification, and understanding precursor lesions to advance targeted therapies and personalized care.
Locoregional Therapies and Radiation for the Treatment of Patients With CCA
June 2025, Vol 6, No 2
Experts have highlighted the latest advancements in locoregional treatments, including hepatic arterial infusion, selective internal radiation therapy, ablation techniques, and histotripsy, offering new hope for improving survival in cholangiocarcinoma (CCA) patients.
Systemic Therapies and Surgery for CCA
June 2025, Vol 6, No 2
Experts discuss advancements in systemic therapies, surgical strategies, and liver transplantation, offering new hope for improving outcomes in patients with cholangiocarcinoma (CCA).
Tinengotinib: A Next-Generation Fibroblast Growth Factor Receptor (FGFR) Inhibitor for CCA
June 2025, Vol 6, No 2
Tinengotinib emerged as a promising next-generation multikinase inhibitor, offering new hope for patients with resistant cholangiocarcinoma (CCA) through its innovative mechanism of action and encouraging clinical trial results.
Advancing Oncology Research Through Novel Endpoints and Consensus-Driven Collaboration
June 2025, Vol 6, No 2
A collaborative roadmap has been unveiled to redefine clinical endpoints, advance precision medicine, and align global efforts in tackling the challenges of rare and aggressive biliary tract cancers.
AI-Driven Approaches in CCA
June 2024, Vol 5, No 2
Three presentations discussed the application of artificial intelligence learning– and machine learning-driven approaches to improve pathology, radiology, and drug discovery processes, showing strong potential for improving outcomes in patients with cholangiocarcinoma.
Cancer Vaccines Targeting WT1 for CCA
June 2024, Vol 5, No 2
Benjamin L. Green, MD, presented Wilms’ tumor 1 vaccine novel adoptive cell therapy approaches for advanced solid cancers, including the role of immunotherapy in treating advanced cholangiocarcinoma.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Profession or Role
Primary Specialty or Disease State